Dynamics of immunity over time: decline of anti-SARS-CoV-2 IgG antibodies and T-cell responses after mRNA vaccination in residents and health care workers in nursing homes and homes with assisted living support.
COVID-19
IgA
IgG
SARS-CoV-2
T cell immunity
immunoglobulin
Journal
GMS infectious diseases
ISSN: 2195-8831
Titre abrégé: GMS Infect Dis
Pays: Germany
ID NLM: 101694381
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
In the present study, we investigated the dynamics of immunity over time by measuring anti SARS-CoV-2 IgG antibodies and SARS-CoV-2 specific T-cell responses (interferon-gamma release assay) after two doses of vaccines in residents and health care workers (HCW). Mostly, 224 (98%) residents and 244 (89%) HCW received two doses of mRNA vaccine (BNT162b2, Pfizer-BioNTech); the rest of the participants received heterologous vaccinations with mRNA and vector vaccines. The study was conducted at the time when the Delta variant of SARS-CoV-2 prevailed. We analyzed blood samples of 228 residents (median age 83.8 years) and of 273 HCW (median age 49.7 years) from five nursing homes and one home for the elderly with assisted living support at one specific time point. Participants received two vaccinations. The blood samples were analyzed for SARS-CoV-2 specific IgG antibody and T-cell responses. The initial immune responses in the younger participants were about 30% higher than in the older age group. Over time the estimated mean of the parameters (estimated from the study sample for the total population) decreased in all groups within the maximum observation period of 232 days. Comorbidities such as coronary heart disease or diabetes mellitus reduced the initial immune responses regardless of age. With regard to measured IgG antibody levels, absolute values decreased over time, whereas the interferon-gamma response remained at a constant level between day 120 and 180 and seemed to be less dependent on the time elapsed after vaccination. Based on our data, it does not seem possible to determine a reliable threshold of robust immunity, but we suggest that high titres of neutralizing capacity and interferon-gamma response might be an indicator of protection against severe COVID-19 courses.
Sections du résumé
Background
UNASSIGNED
In the present study, we investigated the dynamics of immunity over time by measuring anti SARS-CoV-2 IgG antibodies and SARS-CoV-2 specific T-cell responses (interferon-gamma release assay) after two doses of vaccines in residents and health care workers (HCW). Mostly, 224 (98%) residents and 244 (89%) HCW received two doses of mRNA vaccine (BNT162b2, Pfizer-BioNTech); the rest of the participants received heterologous vaccinations with mRNA and vector vaccines. The study was conducted at the time when the Delta variant of SARS-CoV-2 prevailed.
Methods
UNASSIGNED
We analyzed blood samples of 228 residents (median age 83.8 years) and of 273 HCW (median age 49.7 years) from five nursing homes and one home for the elderly with assisted living support at one specific time point. Participants received two vaccinations. The blood samples were analyzed for SARS-CoV-2 specific IgG antibody and T-cell responses.
Results
UNASSIGNED
The initial immune responses in the younger participants were about 30% higher than in the older age group. Over time the estimated mean of the parameters (estimated from the study sample for the total population) decreased in all groups within the maximum observation period of 232 days. Comorbidities such as coronary heart disease or diabetes mellitus reduced the initial immune responses regardless of age. With regard to measured IgG antibody levels, absolute values decreased over time, whereas the interferon-gamma response remained at a constant level between day 120 and 180 and seemed to be less dependent on the time elapsed after vaccination.
Conclusions
UNASSIGNED
Based on our data, it does not seem possible to determine a reliable threshold of robust immunity, but we suggest that high titres of neutralizing capacity and interferon-gamma response might be an indicator of protection against severe COVID-19 courses.
Identifiants
pubmed: 37830111
doi: 10.3205/id000082
pii: id000082
pmc: PMC10565841
doi:
Types de publication
Journal Article
Langues
eng
Pagination
Doc02Informations de copyright
Copyright © 2023 Schiffner et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Front Public Health. 2021 Sep 27;9:732787
pubmed: 34646805
Emerg Infect Dis. 2021 Aug;27(8):2174-2178
pubmed: 34102097
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
PLoS One. 2022 Apr 8;17(4):e0266852
pubmed: 35395052
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Science. 2022 Jan 07;375(6576):22-23
pubmed: 34990231
EClinicalMedicine. 2021 Nov;41:101143
pubmed: 34608454
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Front Aging. 2022 Apr 25;3:883724
pubmed: 35821813
JAMA. 2022 Jan 25;327(4):341-349
pubmed: 35006256
Front Public Health. 2020 Sep 22;8:570543
pubmed: 33072707
J Clin Virol. 2022 Jan;146:105052
pubmed: 34920374
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Nat Microbiol. 2022 Feb;7(2):195-199
pubmed: 35013593